The global leader in developing LAG-3 therapeutics
Australia Biotech Invest & Partnering 30th October 2018
• Globally active biotechnology company with operations in Australia, Europe and U.S.
• Four LAG-3 related product candidates in development in immuno-oncology and autoimmune disease
• Committed partnerships with five of the world’s largest pharmaceutical companies - Merck (MSD), Pfizer/ Merck KGaA, Novartis and GSK, along with Eddingpharm in China
To view Presentation please download PDF attached:
Download this document